Stock comparison
Glaukos
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GKOS
Glaukos
Market cap
$7.06B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GKOS | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 21F | 79B | HALO |
| Benjamin Graham | 56D | 83A | HALO |
| Philip Fisher | 44D | 65B | HALO |
| Peter Lynch | 29F | 53D | HALO |
| Joel Greenblatt | 2F | 40D | HALO |
| Charlie Munger | 30F | 80C | HALO |
| Terry Smith | 30F | 84A | HALO |
Side-by-side metrics
| Metric | GKOS | HALO |
|---|---|---|
| Market cap | $7.06B | $8.1B |
| P/E (TTM) | - | 24.0x |
| EV/EBIT | - | 10.2x |
| ROIC (TTM) | -10.4% | 23.65% |
| Gross margin | 78.08% | 81.24% |
| Net margin | -34.34% | 23.13% |
| Revenue CAGR 5y | 14.62% | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | 0.2x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GKOS leads on
- P/E (TTM)-vs 24.0x+154%
- EV/EBIT-vs 10.2x+110%
- Debt / Equity0.2xvs 1.0x+84%
HALO leads on
- Net margin23.13%vs -34.34%+167%
- ROIC (TTM)23.65%vs -10.4%+144%
- Revenue CAGR 5y33.23%vs 14.62%+56%
- Market cap$8.1Bvs $7.06B+13%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.